- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06936527
XS-03 em combinação com Folfox ou Folfiri e Bevacizumab para tratamento de pacientes com câncer colorretais metastático com mutação RAS (XS-03-II201)
Um estudo clínico de fase IB/II multicêntrico e aberto: visam valer a eficácia e a segurança da comination XS-03 com Folfox ou Folfiri e Bevacizumab em pacientes com câncer colorretal metastático com mutação Ras
XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation
Visão geral do estudo
Status
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Beijing, China
- Beijing Cancer Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria
- Voluntarily participate in the clinical trial and sign the informed consent form.
- Age ≥18 and ≤ 75 years. No gender restrictions.
- Patients with histologically and/or cytologically confirmed metastatic colorectal cancer who are not suitable for surgical treatment.
- Advanced or metastatic colorectal cancer: Stage Ib patients must have received at least one prior systemic therapy; Stage II patients have no prior systemic therapy. For patients with previously neoadjuvant/adjuvant therapy, disease progression must occur no less than 6 months after the end of therapy to be eligible for inclusion.
- Documentation of RAS mutation. The previously gene test report issued by qualified testing institution is acceptable. BRAF status is not restricted.
- Consent to provide tumor tissue samples and peripheral blood for biomarker analysis.
- Has measurable extracranial lesion according to RECIST v1.1 criteria, defined as at least one lesion that has not received radiotherapy. For previously radiotherapy lesion, there must be imaging evidence of progression after radiotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status score 0-1.
- Expected life expectancy ≥ 6 months.
- The patient has adequate hepatic, renal and bone marrow function.
- For a woman of child-bearing potential must have a negative serum pregnancy test within 7 days prior to enrollment. Woman of child-bearing potential and fertile men must agree to use adequate contraception for the duration of study participation and for 6 months after the last dose.
Exclusion Criteria
-
Patients with known high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) primary or metastatic colorectal cancer and suitable for immune checkpoint inhibitor treatment assessed by investigators.
-
Previously received bevacizumab and its biosimilar therapy. (Only for phase II)
-
Central nervous system metastases which are symptomatic or require therapy.
-
Imaging shows major blood vessel invasion (such as the aorta, pulmonary artery, pulmonary vein, vena cava, etc.).
-
Adverse events and/or complications that caused by previous antitumor therapy have not recovered to baseline level or ≤ CTCAE grade 1.
Baseline level or ≤ Grade 1. However, any grade of alopecia, pigmentation, or ≤ Grade 2 peripheral sensory neuropathy, or other conditions assessed by the investigator as having become chronic and not affecting the safety of the study medication are allowed for inclusion.
-
With a history of other malignancies within 5 years or with other malignancies currently prior to screening, except colorectal cancer. Exception: curatively treated early-stage malignancies (in situ carcinoma or stage I tumors), such as adequately treated basal cell or squamous cell skin cancer or in situ cancer of the cervix.
-
Patients have a significant risk of bleeding.
-
Patients have a significant risk of thrombus.
-
Patients have severe cardiovascular disease, including but not limited to: Ischemic heart disease within the past 6 months prior to screening; coronary artery disease post-surgery or stent implantation within 6 months; New York Heart Association (NYHA) functional classification ≥ Class II within 6 months prior to screening; or known left ventricular insufficiency (LVEF <50%);transient ischemic attack or cerebrovascular accident within 6 months prior to screening; uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg) despite standard treatment, or history of hypertensive crisis or hypertensive encephalopathy;severe arrhythmia requiring clinical intervention; any other cardiovascular disease that researchers regard the patient unsuitable for participation in the study.
-
Patients with a significantly increased risk of QTc prolongation.
-
Patients unable to swallow drugs or have severe diseases that significantly affect drug absorption.
-
Patients have one of the following viral active infections: active hepatitis B or C; human immunodeficiency virus (HIV) infection; active syphilis
-
During screening, the presence of interstitial lung disease, interstitial pneumonia, pulmonary interstitial fibrosis requiring therapy, or a history of pneumonia caused by tyrosine kinase inhibitors.
-
Patients received radiotherapy within the past 4 weeks prior to the first first dose of study drug.
-
Patients received therapeutic surgeries (excluding diagnosis, biopsy, or drainage procedures) within the past 4 weeks prior to the first dose of study drug, including local treatments such as radiofrequency ablation for liver metastases, or are expected to have major surgeries during the study period.
-
Severity infection need intravenous infusion of antibiotics, antiviral drugs, or hospitalisation within the past 2 weeks prior to the first dose of study drug.
-
Patients must use strong CYP3A4 inducers or inhibitors within the past 2 weeks prior to the first administration, or during the anticipated study period,
-
History of severe allergy, or known allergy to any active or inactive components of the study drug product.
-
Pregnancy or lactation.
-
Patients with severe diseases of any organs or systems, any clinical or laboratory test abnormalities, or other reasons that investigator assess them unsuitable to participate in this clinical study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Experimental arm 1: XS-03 + FOLFOX/FOLFIRI + Bevacizumab
Phase 1b: XS-03 escalating orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFOX or FOLFIRI and bevacizumab. FOLFOX (85 mg/m^2 oxaliplatin, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU) , 5 mg/kg bevacizumab FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU), 5 mg/kg bevacizumab |
XS-03 orally Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously |
|
Experimental: Experimental arm 2: XS-03 + FOLFOX/FOLFIRI + Bevacizumab
Phase 2: XS-03 Recommended Phase 2 Dose (RP2D) and selected one more dosage orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combinationwith FOLFOX or FOLFIRI and bevacizumab. FOLFOX (85 mg/m^2 oxaliplatin, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU) , 5 mg/kg bevacizumab FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU), 5 mg/kg bevacizumab |
XS-03 orally |
|
Comparador Ativo: Comparator: FOLFOX/FOLFIRI + Bevacizumab
Phase 2: Comparator arm treat with FOLFOX or FOLFIRI + bevacizumab intravenously. FOLFOX (85 mg/m^2 oxaliplatin, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU) , 5 mg/kg bevacizumab FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil (5-FU), and 2400 mg/m^2 continuous intravenous infusion 5-FU), 5 mg/kg bevacizumab |
Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Phase 1b: Number of participants with Dose-limiting Toxicities (DLTs) in experimental arm of XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab
Prazo: up to day 28
|
Dose-limiting toxicities were defined as events related to XS-03 that were considered an adverse reaction or suspected adverse reaction during the first cycle of treatment |
up to day 28
|
|
Phase 1b: Determine the Maximum Tolerated Dose (MTD) in experimental arm of XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab
Prazo: up to day 28
|
MTD is defined as at most 1 patient out of 6 experiencing DLT |
up to day 28
|
|
Phase 2: Objective Response Rate (ORR) of two experimental arms and comparator arm
Prazo: up to 18 months after first dose of last patient
|
Defined as the percentage of participants that achieve a best overall response of complete response (CR) or partial response (PR) (per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria) |
up to 18 months after first dose of last patient
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Fase 1b: taxa de resposta objetiva (ORR) de todos os participantes tratados
Prazo: até 18 meses após a primeira dose do último paciente
|
até 18 meses após a primeira dose do último paciente
|
|
|
Número de participantes com mudança clinicamente significativa em relação à linha de base no monitoramento de segurança
Prazo: até 28 dias após a última dose de medicamento de estudo
|
até 28 dias após a última dose de medicamento de estudo
|
|
|
Duration of response (DOR) of all treated participants
Prazo: up to 18 months after first dose of last patient
|
Duration of response defined as time from when response was first documented until first documented disease progression or death, whichever occurs first. |
up to 18 months after first dose of last patient
|
|
Progression-free survival (PFS) of treated participants
Prazo: up to 18 months after first dose of last patient
|
as determined based on RECIST version 1.1 criteria |
up to 18 months after first dose of last patient
|
|
Overall survival (OS) of treated participants
Prazo: up to 18 months after first dose of last patient
|
Time in months from date of first dose for phase 1b and randomization for phase 2 to death due to any cause |
up to 18 months after first dose of last patient
|
|
Number of Participants With Adverse Events (AEs) of treated participants
Prazo: up to 28 days after last dose of study drug
|
The severity of each AE will be graded using the Common Terminology Criteria for Adverse Events (CTCAE). |
up to 28 days after last dose of study drug
|
|
Number of Participants With dose adjustment
Prazo: up to 28 days after last dose of study drug
|
AE associated with dose reduction, interruption and discontinuation |
up to 28 days after last dose of study drug
|
|
Time to Reach Maximum Peak Plasma Concentration (Tmax)
Prazo: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
|
Pharmacokinetic parameter |
From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
|
|
Maximum Plasma Concentration(Cmax)
Prazo: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
|
Pharmacokinetic parameter |
From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
|
|
Area under the plasma concentration versus time curve from time zero to the last measurable concentration(AUC0-t)
Prazo: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
|
Pharmacokinetic parameter |
From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
|
|
Elimination Half-life (T1/2)
Prazo: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
|
Pharmacokinetic parameter |
From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
|
|
Systemic Clearance From Plasma Following Extravascular Administration (CL/F)
Prazo: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
|
Pharmacokinetic parameter |
From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
|
|
The volume of distribution(Vd/F)
Prazo: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
|
Pharmacokinetic parameter |
From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
|
|
Average concentration at steady state(Cavg,ss)
Prazo: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
|
Pharmacokinetic parameter |
From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
|
|
Minimum observed concentration at steady state(Cmin,ss)
Prazo: From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
|
Pharmacokinetic parameter |
From pre-dose on day 1 of cycle 1 to day 5 of cycle 3 (28-day cycle length)
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- XS-03-II201
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .